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1. Introduction 
The completion of Human Genome Project and advancement of analytical technology with 
the large-scale identification of genome polymorphisms have contributed to the field of 
forensic science, especially in the studies on genetic basis of most important inherited 
arrhythmia syndromes responsible to sudden cardiac death, a major cause of death 
worldwide, and of individual differences in response to potential toxicants, with a new 
emerging area of interest, the so called pharmacogenetics. 
The term pharmacogenetics was first used in the late 1950s (Clayman, 1952) and can be 
defined as the study of variability in drug responses as a function of genetic differences 
among individuals; applied to nontherapeutic foreign substances, collectively referred to 
as xenobiotics, the equivalent term toxicogenetics is used (Nebert, 1999; Mancinelli, 2000; 
Park and Pirmohamed, 2001; Roses, 2002; Wolf, 2000). The later coined term 
'pharmacogenomics' usually refers to changes in gene expression as a consequence of 
drug exposure. However, the two terms, pharmacogenetics and pharmacogenomics, are 
often used synonymously. 
One of the goals of pharmacocogenetics is the identification of the molecular genetic bases 
for interindividual variations in susceptibility to the anticipated effects of a drug or of 
xenobiotics (Pirmohamed and Park, 1999). If we want to provide a modern interpretation of 
the famous assertion of Paracelsus (1493-1541), it is true that "the dose makes the poison", 
but in different degrees, depending on the genetic characteristics of individuals.  
There is no doubt that adverse drug reactions (ADRs) are a common cause of morbidity and 
mortality, despite extensive and well-regulated registration processes for proving drug 
efficacy and drug safety, and are associated with substantial costs of medical care (Lazarou, 
1998; Pirmohamed, 1999).  
Genetic studies could also clarify the origins of addictions, a diverse set of common, 
complex diseases, that are to some extent tied together by shared genetic and environmental 
etiological factors (Goldman, 2005; Kendler, 2003). The use and abuse of legal and illegal 
substances is a worldwide public health priority with repercussions extending from the 
level of the individual to the family, community, and society.  
This chapter will focus on: a) adverse drug reactions; b) drug addiction; c) variability in the 
human genome; d) pharmacogenetic variability in drug response; e) genetic approaches to 
understand the individual differences in susceptibility to drugs/xenobiotics responses; f) 
ethical issues relating to the collection of genetic data. 
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2. Adverse drug reactions 
Any substance that is capable of producing a therapeutic effect can also produce unwanted 
or adverse effects; the risk of such effects ranges from near zero to high (Edwards, 2000). An 
adverse drug reaction (ADR), according to the World Health Organization definition, is “a 
response to a drug that is noxious, unintended, and undesired effect of a drug, which occurs 
at doses used in man for prophylaxis, diagnosis, or therapy of disease, or for modification of 
physiological function”. This definition excludes therapeutic failures, intentional and 
accidental poisoning (ie, overdose), and drug abuse. Also, this does not include adverse 
events due to errors in drug administration or non-compliance (taking more or less of a 
drug than the prescribed amount); using this narrow definition avoids overestimating the 
ADR incidence (Lazarou, 1998). The terms adverse reaction and adverse effect are 
interchangeably, but must be kept in mind that is the “drug”  that has an adverse effect 
whereas it is the “patient” that experience an adverse reaction. However, the two terms 
must be distinguished from “adverse event”, that is an averse outcome that occurs while a 
patient is taking a drug, but is not necessarily attributable to it (Edwards, 2000).  
The interest in ADRs was stimulated by the thalidomide tragedy in the 1960s and, over the 
past several years, ADRs have gained worldwide attention: the Food and Drug 
Administration (FDA) has planned a system of pharmacovigilance to be followed by 
regulatory agencies, pharmaceutical companies, and individual health care providers (U.S. 
Department of Health and Human Services Food and Drug Administration, 2005). 
The occurrence of ADRs is associated with morbidity and mortality and substantial costs of 
medical care. Numerous studies provide a wide range of epidemiological data regarding 
adverse drug reactions. ADRs are one of the top ten causes of death in the United States, 
causing over 100 000 deaths annually; approximately 2–5% of all hospital admissions can be 
attributed to adverse drug reactions (Lazarou, 1998). In a study performed in 1999 in 
emergency departments of French public hospitals, out of a total of 1937 patients consulting, 
328 (21%) of these patients consulted an physician because of an ADR (Queneau, 2007). 
During the year 2000, a prospective Italian study was performed in two observational 
periods of 10 days each in 22 Italian emergency departments: on 18 854 enrolled patients, 
629 (3.3%) were affected by ADR and among these, 244 (38.8% of ADR patients) reported a 
serious event (Trifirò G, 2005). In a prospective Scandinavian study with 13.992 patients of 
internal medicine, the incidence of lethal ADR was estimated to be 0.95% (Ebbesen, 2001). 
Another prospective study conducted in the UK demostrated that about 6.5% of hospital 
admissions were ADR related in 18.820 patients (Pirmohamed, 2004). In a nationwide study 
in Spain, during a six-year period (2001-2006), the total number of hospitalized patients with 
ADR diagnosis was 350 835, 1.69% of all acute hospital admissions (Carrasco-Garrido, 2010); 
in The Netherlands, in 2001, 12 249 hospitalisations were coded as ADR related, 1.83% of all 
acute hospital admissions (van der Hooft, 2010).  
Unfortunately, many physicians still consider adverse drug reactions to be an exception, 
rather than a primary diagnosis and adverse drug reactions have become cases of medical 
professional liability, with great increase of lawsuits (Wooten, 2010).  
The classification of ADRs distinguished dose-related and non-dose related reactions, 
named type A and type B, respectively; type A reactions are common, predictable and 
therefore potentially preventable, based on the drug’s pharmacological action, while type B 
reactions are more troublesome, uncommon and unpredctable. More recently, additional 
types were added, such as chronic (type C) and delayed (type D) effects, as well as 
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withdrawal or end of use syndromes (type E) and therapeutic failures (type F) (Edwards, 
2000). 
Different subjects with the same diagnosis could respond differently to the same drug 
administered at the same dose, with a diminished, absent or excessive response or 
interaction with other drugs (Mancinelli, 2000; Meyer, 2004). Potential risk factors for ADRs 
include patients’ age, sex, race, nutritional status, organ function, especially of liver and 
kidneys, co-morbidities, co-medication, as well as some lifestyle variables (smoking habits, 
concomitant use of alcohols and drugs) and, of course, genetics. Some ADRs caused by 
genetic variation, previously considered unpredictable, may now be preventable. In general, 
genetic factors are estimated to account for 15-30% of interindividual differences in drug 
metabolism and response, but for certain drugs this can be as high as 95% (Evans, 2004; 
Weinshilboum, 2003)  
ADRs may be reduced by means of the introduction of “personalized medicine”, which 
anticipates the screening of patients for polymorphisms associated with a drug response, 
usually performed prior to the initiation of therapy. Despite significant progress in this field, 
only few drugs, such as cetuximab, dasatinib, maraviroc and trastuzumab, require a 
pharmacogenetic test before being prescribed: there are several gaps that limit the 
application of pharmacogenetics based upon the complex nature of the drug response itself 
(Gervasini, 2010). 
This kind of policy foresees the introduction of new sophisticated tests, especially in the 
field of genetics, like DNA microarrays or DNA chips. 
3. Drug addiction 
Drug addiction is a chronic, relapsing disorder in which compulsive drug-seeking and drug-
taking behavior persists despite serious negative consequences; continued use induces 
adaptive changes in the central nervous system that lead to tolerance, physical dependence, 
sensitization, craving, and relapse (Goodman, 2008). This mental health disorder imposes a 
significant burden on those directly affected, health care systems, and society in general, 
since it is associated with considerable morbidity and mortality, violence, and legal issues. 
According to World Health Organization (WHO) figures, about 2 billion people worldwide 
consume alcoholic beverages, 1.3 billion nicotine and 185 million illegal drugs. In Europe the 
use of alcohol, nicotine and illicit substances is responsible for respectively 10%, 12% and 2% 
of the total cost of illness. (WHO, 2002). 
Polydrug use of psychoactive substances, legal and illegal, characterizes and defines the 
style  of consumption prevailing  more and more common among younger subjects. There is 
another emerging market worldwide for an increasing number of psychoactive substances 
whose compositions are not well known and whose effects have not yet been recorded by 
physicians and they are difficult to recognize, delaying the diagnosis and treatment of 
patients themselves. 
In addition there is another phenomenon in recent years: it is a marked shift in the 
marketing of licit and illicit drugs through online pharmacies, without requiring a 
prescription. The new generations are particularly vulnerable to this risk because they are 
very prone to use new technologies. 
The nonmedical use of a prescription or over-the-counter (OTC) medication is another 
significant international emerging problem. OTC medications are pharmaceuticals that do 
not require a prescription and are sold on the shelves of markets, stores and pharmacies. 
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The several classes of medications that are commonly abused include: analgesics opioids, 
which are most often prescribed to treat severe pain (morphine, oxycodone, hydrocodone, 
hydromorphone, codeine); central nervous system depressants, commonly prescribed to 
treat anxiety and sleep disorders (barbiturates and benzodiazepines); stimulants, which are  
used primarily to treat attention defict disorder, attention defict hyperactivity disorder 
(ADHD) and narcolepsy (dextroamphetamine and methylphenidate). The OTC medicines, 
such as certain cough suppressant (dextromethorphan), sleep aids (doxylamine), 
antihistamines (diphenhydramine), decongestants and others can be abused for their 
psychoactive effects (Lessenger, 2008). 
According to figures reported by NIDA, in 2009 approximately 7 million (M) reported past 
month non-medical use of psychotherapeutic drugs (2.8 percent of the U.S. population). The 
medications most commonly abused are: pain relievers (5.3 M), tranquilizers (2.0 M), 
stimulants (1.3 M), sedatives (0.4 M). The abuse of drugs is particularly problematic in 
adolescents, shows that in boys aged 12 to 17 years 8,3% reported abuse of Vicodin 
(hydrocodone) and 5% of Oxicontin (oxycodone hydrochloride) (NIDA, 2010). 
All substances that are abused have ability to induce dependence and withdrawal. 
The current challenge is to transfer the important increase of the knowledges of addiction's 
neurobiology in patients with addiction problems and to identify specific genes responsible 
for the particular vulnerability or resistance to addiction. Some schools of thought contend 
that addiction is entirely preventable through proper legislative action and individual 
choice, and claim that genetic research in this field is to assume a role as a low priority 
(Merikangas, 2003). Genetic research, however, plays a very important role, since the origins 
of addiction susceptibility are complex and wide-ranging; the underlying genetic factors 
need to be identified to solve the puzzle of what causes these pervasive and relatively 
intractable disorders (Goldman, 2005). 
Both genetic and environmental variables contribute to the initiation of use of addictive 
agents and to the transition from use to addiction (Bevilacqua, 2009). Evidence from twin 
and adoption studies suggest that 40-60% of the risk of developing substance abuse 
disorders is due to genetic factors, with the percentage depending on the substance (Nestler, 
2000). The addiction are complex disorders involving multiple genes and environment 
interaction (G x E). The genetic influences are more prominent in the later phases of 
individuals’ progression toward substance dependence; this variation could add to allelic 
variations that could produce effects on addiction susceptability phenotypes by other routes 
that could include: differences in pharmacokinetic characteristics of the substance such as 
metabolism and biodistribution; differences in drug’s rewarding properties; differences in 
traits manifest by the addict, including personality differences; differences in addict’s 
psychiatric comorbidities (Uhl, 2004). This suggests two broad types of genetic 
predisposition to addiction: genetic profiles that make people more likely to find the acute 
effect of drugs rewarding and genetic profiles that make people more or less likely to 
developing addiction if they use drugs (EMCDDA, 2009). Finally, evidence indicates that 
there is a genetic predisposition that is shared between the different substance use disorders;  
nearly 25-36% of the genetic influences of alcohol, nicotine and cannabis problem use is 
attributable to overlapping factors (Young, 2006).  
The inheritance of addictions has been evaluated in many ways, including studies on 
families and adoptees, but the main reference of our knowledge comes from the patterns of 
correlations in monozygotic (MZ) and dizygotic (DZ) twins. The overall genetic influence 
for substance use disorders has proved to be consistent and heritabilities for most substance 
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use disorders are estimated to be moderate to high (Wong, 2008). This moderate to high 
inheritance may seem paradoxical: addiction depends initially on individual choice to use 
an additive agent. Cocaine and opiates, among the most addictive of substances, are among 
the most heritable; in contrast, hallucinogens, are among the least addictive, and are also the 
least heritable (Bevilacqua, 2009). 
The genes involved in the of the condition are very numerous (Kreek, 2005). 
The phenotype for addiction to drugs is not well defined, and the heritability of addiction to 
drugs of abuse is far from clear. Knowledge of genetic factors in etiology and treatment 
response may enable the individualization of prevention and treatment, as well as the 
identification of new therapeutic targets (Buckland, 2008). 
4. Variability in the human genome 
Individuals are all different from each other and much of this difference has a genetic basis. 
Two unrelated human beings also share 99.9% of their genomic sequence, and could be 
considered genetically almost identical: the difference has been estimated to be of 0.1% 
overall, but still, this means that there are at least several million nucleotide differences per 
individual. There are, on average, three million genetic differences between any two people; 
the human genome contains approximately 3 billion base pairs of DNA and the variability 
of genetic material between any two individuals averages approximately one variation for 
every 1,000. 
This genetic diversity in most cases have no functional significance, but in some cases have 
important consequences (Marchant, 2003). The most dramatic examples are seen with 
inherited disorders, where small alterations in gene sequence can result in premature death 
or severe disability (Alberts, 2002; Habener and Williams, 2002; King, 2002). It is also 
responsible of the phenotypic diversity, which results in the heterogeneous capacity of each 
individual to respond to exogenous substances, such as drugs and xenobiotics, and in the 
different susceptibility to induce adverse health effects. 
The types of genetic variations used in these studies have changed in the past 25 years and 
can be classified into five major classes: RFLP (restriction fragment length polymorphism), 
VNTR (variable number of tandem repeat), STR (short tandem repeat), SNP (single-
nucleotide polymorphism) and CNV (copy-number variation); furthermore, construction of 
the international SNP database and recent development of high-throughput SNP typing 
platforms enabled us to perform genome-wide association studies, which have identified 
genes or genetic variations susceptible to common diseases or those associated with drug 
responses (Nakamura, 2009).  
SNPs are found at a frequency of about 1:1000 bases in humans and they are changes in a 
single base at a specific position in the genome, in most cases with two alleles. By definition, 
the more rare allele should be more abundant than 1% in the general population; if the 
variant is rare, with a frequency below 0.1%, it is referred to as a mutation. More than 99% 
of these genetic variations are biologically silent, while some polymorphisms can affect 
biological function according to their position within the genome. 
Following the  scheme of Orphanides and Kimber (2003), it is possible to distinguish: 
1. SNPs that fall within the coding region of a gene can give rise to a protein that has an 
amino acid substitution, or is truncated, causing a change in activity, localization, or 
stability; 
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2. SNPs that induce shifts in translational reading frames will lead to the synthesis of 
proteins with altered aminoacid sequence and, perhaps, activity; 
3. nucleotide alterations in the regulatory regions of a gene can also have a significant 
impact on the integrity of protein function; 
4. polymorphisms in promoter regions may change the regulation and level of expression 
of a protein, whereas those that fall near intron-exon junctions may cause alterations in 
mRNA splicing; 
5. more dramatic polymorphisms involving larger segments of the genome include gene 
deletions, gene conversions, and gene duplications (Orphanides and Kimber, 2003). 
5. Pharmacogenetic variability in drug response  
Gene polymorphisms account for the polymodal distribution of the frequency of response to 
a drug in a non-homogeneous population, i.e. one encompassing multiple genetic profiles 
capable of affecting response. 
Current pharmacogenetic studies are exploring individual responses to drugs in relation to 
the genetic variations in the proteins involved in pharmacokinetics (absorption, distribution, 
metabolism and excretion) and pharmacodynamics (receptors, ion channels and other 
enzymes) (Roses A, 2000; Nebert, 2008) (figure 1).  
 
 
Fig. 1. Pharmacogenetic variations affecting the individual response to a drug 
Drug-metabolizing enzymes (DMEs) play a key pharmacokinetic role (Meyer, 1997). Drugs 
are turned to metabolites in the liver, by transformation of functional groups (phase I 
reactions) and subsequent conjugation with endogenous lipophilic substances to form 
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inactive compounds (phase II reactions) for ready excretion in urine or bile. Oxidative drug 
metabolism is mainly catalyzed by the enzymes of the large CYP450 gene family, that 
contains 57 functional genes and 58 pseudogenes playing an important role in the 
metabolism of therapeutic drugs and other xenobiotics. CYP450 are so named because they 
are bound to membranes within a cell (cyto) and contain a heme pigment (chrome and P) 
that absorbs light at a wavelength of 450 nm when exposed to carbon monoxide. The 
corresponding genes are highly polymorphic and genetic variability underlies 
interindividual differences in drug response. CYP2D6, 2C19, and 2C9 polymorphisms 
account for the most frequent variations, since almost 80% of drugs in use today are 
metabolized by these enzymes (Danielson, 2002; Ingelman-Sundberg, 1999; Nebert, 2002; 
Nelson, 1999; Zhou, 2009). The polymorphisms of CYP2D6 significantly affect the 
pharmacokinetics of about 50% of the drugs in clinical use (De Gregori M, 2010). 
The CYP450 enzimes convert the substances into electrophilic intermediates, which are then 
conjugated by phase II enzymes, of which the most important are the highly polymorphic 
UDP-glucuronil transferase, sulfotransferase, catechol-O-methyltransferase (COMT) and 
glutathione transferase, to facilitate substrate excretion by turning them into more water-
soluble forms.  
All these factors determine the trend of concentration over time and therefore the 
effectiveness of drugs and duration of effect. DME genetic variations result in marked 
phenotypic consequences; these range from poor metabolizers (where toxic drug effects may 
arise due to the absence of the gene product) to ultrarapid metabolizers (where therapeutic 
failure may be induced by the indicated dosage, with the risk of achieving high plasma 
concentrations and concentration-dependent side effects due to gene overexpression). The 
resulting phenotypes are poor (PMs), intermediate (IMs), extensive (EMs) and ultrarapid 
(UMs) metabolizers. 
To leave the cell, some drugs are actively transported by membrane transporter proteins. 
The major transporter enzymes are MDR1 (multidrug resistance proteins), MRP (multidrug 
resistance-associated proteins) and OATP (organic anion-transporting polypeptides), where 
several genetic polymorphisms have been demonstrated. MDRs are transmembrane 
transporters of the large ABC protein family: P-glycoprotein (P-gp, or MDR1/ABCB1), the 
best known, is highly polymorphic. It can influence substrate absorption at the level of the 
blood brain barrier; high P-gp concentrations can limit entry of the required amount of 
drug, whereas low levels may result in abnormal accumulation. Recently, allele frequencies 
and findings regarding functional variants in drug transporter systems were reported in an 
interesting review (Kroetz, 2010). 
Pharmacodynamic processes mediate the biochemical and physical effects of drugs on the 
organism. Variations in the sequence of the genes encoding the primary therapeutic target, 
such as receptors and ion channels, are capable of inducing protein forms with different 
functional characteristics. This can account for abnormal drug responses, which may also 
underpin some adverse reactions. 
Recently, researchers are focusing on most important genetic variations that could 
contribute to the initiation of use of addictive agents and to the transition from use to 
addiction. The complex genetic constitution is partly accounted for by heterogeneity and 
polygenicity: the first assumes that a single or a few genetic variation(s) determine 
vulnerability and resiliency, but different alleles would lead to the same clinical presentation 
in different individuals; the second, on the other hand, assumes that a phenotype is a result 
of simultaneous function of multiple genetic variants (Goldman, 2005; Wong, 2008).  
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Pharmacogenetic studies can assess the effects of genetic variation on the risk for particular 
phenotypes for addiction, for example being an alcoholic (Onori, 2010; Buscemi, 2011). In 
recent years abundant evidence has accumulated demonstrating that alcoholism, a major 
health and social issue, being one of the most frequent disease and cause of premature 
death, is a multifaceted disease of the brain, caused by numerous genetic, neurobiological, 
environmental factors that are still not yet fully understood. Numerous genes are up- 
and/or down-regulated by alcohol exposure: the ethanol-responsive genes mainly encode 
functional proteins such as proteins involved in nucleic acid binding, transcription factors, 
selected regulatory molecules, and receptors. Currently there are only three medications 
approved by the U.S. Food and Drug Administration (FDA) for use in the treatment of 
alcohol abuse and alcohol dependence: the aldehyde dehydrogenase inhibitor disulfiram, 
the micro-opioid receptor antagonist naltrexone, and the N-methyl-D-aspartate (NMDA) 
receptor inhibitor acamprosate (Wang, 2010).  
6. Pharmacogenetic approaches 
Pharmacogenetic studies can be categorized into two methodologic approaches: genome-
wide linkage analysis and candidate gene approach.  
Linkage analysis is applied to families with several affected individuals, to establish 
whether specific alleles of marker genes are found more often in individuals with the 
disease than in healthy subjects. The whole genome is analysed using markers that are 
uniformly distributed on all chromosomes, seeking chromosome regions that could contain 
genes involved in complex disorder susceptibility. The linkage is sought only in recent 
ancestors. Since only a small number of recombination events are involved, the gene regions 
detected by linkage analysis are likely to be large and to encompass hundreds or even 
thousands of genes. Genetic association studies assess correlations between genetic variants 
and trait differences on a population scale and they have been used widely to identify 
regions of the genome and candidate genes that contribute to complex disease. 
A disease-associated SNP that falls within a gene can provide information on the 
mechanistic basis for disease, while a SNP that is in linkage disequilibrium with a genetic 
allele that confers disease predisposition may be used to identify susceptible individuals, 
and naturally this can include those genetic variations that influence relative susceptibility 
or resistance to toxicants (Roses, 2000). The common errors encountered in association 
studies of complex diseases are the small sample size, subgroup analysis and multiple 
testing, random error, poorly matched control group, failure to attempt study replication 
and to detect linkage disequilibrium with adjacent loci, overinterpreting results and positive 
publication bias, unwarranted candidate gene declaration after identifying association in 
arbitrary genetic region (Cardon, 2001). Despite these known limitations, the power of 
association analysis to detect genetic contributions to complex disease can be much greater 
than that of linkage studies (Risch, 2000). 
Association studies can be distinguished into family-based, which use the transmission 
disequilibrium test, and population-based, which use case-control testing. Case-control 
studies compare genes from two groups of individuals, healthy and diseased. Ideally, the 
two groups should be homogeneous, with subjects matching for measures like age, 
ethnicity, years of education, and marital status, and differing only in terms of the disease 
studied. The allele frequency of the gene markers (e.g. SNPs) in or close to the genes are 
analysed and frequency differences between the groups taken to indicate that the gene 
contributes to the disease.  
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Association studies draw from historic recombination so disease-associated regions are 
extremely small in outbred random mating populations, encompassing only one gene or 
gene fragment. As the disease mutation is transmitted from one generation to the next, 
recombination will separate it from the alleles of its original haplotype. 
A specific genetic profile, or haplotype, i.e. the combination of allelic states in a set of 
polymorphic markers found on the same chromosome, could be identified by association 
studies by analyzing a number of markers of a given chromosome region in a group of 
affected subjects and in a control group (case-control study). Different haplotypes can be 
found in a population as a result of mutation or genetic recombination. The recombination is 
principally determined by the genetic distance between markers and by the propierties of 
the locus where they are found (recombination hotspots). Markers that do not undergo 
recombination are characterized by linkage disequilibrium (LD). The tendency of some 
alleles at distinct loci to be co-inherited, due to reduced rates of, or absent, genetic 
recombination may lead to their association in a population, i.e. to LD. Recent LD studies by 
analysis of SNP haplotypes have suggested a block structure, at least in some portions of the 
genome. Haplotype blocks appear as regions made up of consecutive alleles that are co-
inherited. Given the limited haplotype diversity within blocks, several SNPs will be 
redundant, enabling a minimum number of informative markers to be used to identify the 
common haplotypes in each block: these markers are called tag-SNPs. Different block 
structures can be found in different populations, with significant implications for association 
studies, since the tag-SNPs identified in a population will be useless in another if they are 
found in different blocks.  
7. Ethical issues 
It is necessary to make a reflection on how informations from the human genome will be 
used. The collection of genetic data has attracted much public attention for the possible 
ethical, moral and political issues relating to the use of these informations. 
Genome-wide association studies trying to identify genes that contribute a small risk to 
common diseases can only be performed on an international scale; meanwhile, it is 
becoming more and more clear that genomic information is hard to hide. Thus the 
traditional promise in research that privacy will be protected appears to be less realistic. The 
deciphering of the genetic code may pose a threat to the protection of one’s privacy; some 
variants that predict drug response are also markers for disease predisposition. This may 
subsequently lead to medico-legal implications, such as the issue of data confidentially: 
whether employers and insurance companies should given rights to assess the genetic data 
(Koo, 2006). Access to genetic might lead to discrimination of individuals with an 
unfavourable genetic constitution; for example, individuals who have a genetic 
predisposition for a certain condition, or who would only tolerate expensive drugs, might be 
charged higher insurance premiums (Vijverberg, 2010). 
Most European countries have adopted genetic anti- discrimination legislation; Belgium was 
the first in 1990, and many countries followed. After a 13-year battle in Congress-longer 
than it took to map the human genome-the Genetic Information Nondiscrimination Act 
(GINA) was passed into law on 21 May 2008. Francis Collins, the director of the National 
Human Genome Research Institute, said that the success of personalized medicine hinged 
on the passing of the legislation.  
Van Hoyweghen and Horstman state that many European genetic non-discrimination laws 
only provide the illusion of protection and the protection against potential risks of 
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discrimination based on predictive medical information is still so far. Some insurance 
companies may still use genetic test results or genetic information derived from physician 
records or insurance questionnaires (Van Hoyweghen, 2008). This practice is mainly caused 
by ignorance, confusion and misunderstanding, but also due to the lack of clear legal 
definitions of ‘genetic data’ and ‘genetic tests’(Vijverberg, 2010). The definitions of genetic 
testing used by 65 organisations and entities, including genetics professional organisations, 
insurance organisations, pharmaceutical companies, and legal organisations, was reviewed; 
it was found that the definitions used were extremely variable; ranging from DNA testing 
solely, to any source that can provide unambiguous genetic information, including family 
history (Sequeiros, 2005).  
It has been suggested that potential problems with the ethical use of this kind of genetic data 
can be minimized by selecting SNPs that are of pharmacogenetic and toxicogenetic value, 
while avoiding those that predict genetic disease (Roses, 2002). 
Toxicogenetics can learn from the forensic sciences: the widely used technique of “genetic 
fingerprinting” uses a small number of highly polymorphic, unlinked genetic markers that 
have no known implications to the health of an individual (Orphanides and Kimber, 2003).  
8. Conclusion 
The potential of pharmacogenetics to improve the clinical practice is only at the very 
beginning but will present an important biomedical tool in the post-genomic era. The aim is 
to aid physicians in the prescription of the right medicine to a person in an attempt to obtain 
maximum efficacy and minum toxicity based on a genetic test, according the new strategy 
named “personalized medicine”: prescribing the right drug in the right dose to the right 
patient according to specific health needs and individual characteristics. 
Advanced diagnostic analyses, genetic counselling, and interdisciplinary and 
multidisciplinary approach, involving neurobiological, genetical, toxicological, 
psychological, and social sciences,  should be integral parts of forensic practice. 
Although a relatively novel concept in the forensic context, pharmacogenetics has the 
capability to assist in the interpretation of drug related deaths, particularly in unintentional 
drug poisonings where the cause of death remains unclear (Pilgrim, 2010). The 
recommendation number eleven of the report from the National Academy of Sciences (NAS) 
titled “Strengthening Forensic Science in the United States: A Path Forward” is concerned 
with improving medicolegal death investigations: “Best practices should include the 
utilization of new technologies such as laboratory testing for the molecular basis of 
diseases”. 
The forensic science community, however, has not yet fully received this directive and only 
few studies to date have been able to ascertain a correlation between genotype and 
phenotype for a limited number of drugs and to establish a link with the  death (Koski, 2006; 
Koski, 2007; Launiainem, 2010; Levo, 2003). 
The correlation between genotype and phenotype still remains a limitation in a molecular 
autopsy ant it is complicate for a number of reason. Only individuals completely lacking the 
enzyme activity (PMs) are highly correlated with the expected phenotype. There is 
substantial overlap in activity within and between the other phenotypic classes: subjects 
with identical genotypes may also exhibit different phenotypic activities which may be 
explained by population-specific factors, such as unidentified genetic, such as other enzyme 
and proteins, and non-genetic factors, such as diet. In addition, the funtional consequence of 
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the genetic variation may be substrate (e.g. drug or its metabolite) specific (Gaedigk, 2008; 
Sajantila, 2010).  
The new opportunities, offered by pharmacogenetics, to analyse the genetic variations 
related to the risk of ADRs or to susceptibility to drug addiction are of considerable interest 
to forensic scientists, for their role in the evaluation of drug addiction in its various phases 
of development, from beginning to end stage. A better understanding of genetic 
susceptibility to addiction may be also useful for ascertaining the causes and circumstances 
of death. Some gene variants may, in fact, determine in some individuals more sensitive to 
the substance, with an increased risk of toxic effects, even death. 
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